eISSN: 2354-0265
ISSN: 2353-6942
Health Problems of Civilization Physical activity: diseases and issues recognized by the WHO
Current issue Archive Online first About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
Share:
Send email
Share:
Review paper

NEWLY-EMERGING SIDE EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE USAGE ASSOCIATED WITH WEIGHT LOSS TREATMENT

Paula Bieganek
1
,
Bartosz Sadłowski
1
,
Stanisław Łukaszewicz
1
,
Piotr Pawłowski
2
,
Julia Rybak
3
,
Jakub Kordialik
4
,
Julia Koćwin
1
,
Sandra Sarnacka
5
,
Michał Tokarski
6
,
Angelika Banasiak
7

  1. Military Medical Academy Memorial Teaching Hospital of the Medical University of Lodz, Central Veteran Hospital, Lodz, Poland
  2. S. Zeromski Specialist Hospital, Cracow, Poland
  3. Faculty of Medicine, Medical College, Jagiellonian University, Cracow, Poland
  4. Karol Jonscher Municipal Medical Center, Lodz, Poland
  5. Mikolaj Pirogow Provincial Specialist Hospital, Lodz, Poland
  6. Maria Skłodowska-Curie Specialist Hospital, Brzeziny, Poland
  7. Nicolaus Copernicus Specialist Hospital, Lodz, Poland
Health Prob Civil.
DOI: https://doi.org/10.5114/hpc.2024.140505
Online publish date: 2024/06/13
Article file
- Bieganek et al.pdf  [0.49 MB]
Get citation
 
PlumX metrics:
 
1. Xie Z, Yang S, Deng W, Li J, Chen J. Efficacy and safety of liraglutide and semaglutide on weight loss in people with obesity or overweight: a systematic review. Clin Epidemiol. 2022; 14: 1463-1476. https://doi.org/10.2147/CLEP.S391819
2. Son JW, Kim S. Comprehensive review of current and upcoming anti-obesity drugs. Diabetes Metab J. 2020; 44(6): 802-818. https://doi.org/10.4093/dmj.2020.0258
3. Singh G, Krauthamer M, Bjalme-Evans M. Wegovy (semaglutide): a new weight loss drug for chronic weight management. J Investig Med. 2022; 70(1): 5-13. https://doi.org/10.1136/jim-2021-001952
4. Gadde KM, Martin CK, Berthoud HR, Heymsfield SB. Obesity: pathophysiology and management. J Am Coll Cardiol. 2018; 71(1): 69-84. https://doi.org/10.1016/j.jacc.2017.11.011
5.
6. Ard J, Fitch A, Fruh S, Herman L. Weight loss and maintenance related to the mechanism of action of glucagon-like peptide 1 receptor agonists. Adv Ther. 2021; 38(6): 2821-2839. https://doi.org/10.1007/s12325-021-01710-0
7. Ahmad NN, Robinson S, Kennedy-Martin T, Poon JL, Kan H. Clinical outcomes associated with anti-obesity medications in real-world practice: a systematic literature review. Obes Rev. 2021; 22(11): e13326. https://doi.org/10.1111/obr.13326
8. Kanoski SE, Hayes MR, Skibicka KP. GLP-1 and weight loss: unraveling the diverse neural circuitry. Am J Physiol Regul Integr Comp Physiol. 2016; 310(10): R885-95. https://doi.org/10.1152/ajpregu.00520.2015
9. Smits MM, Van Raalte DH. Safety of semaglutide. Front Endocrinol (Lausanne). 2021; 12: 645563. https://doi.org/10.3389/fendo.2021.645563
10. Bergmann NC, Davies MJ, Lingvay I, Knop FK. Semaglutide for the treatment of overweight and obesity: a review. Diabetes Obes Metab. 2023; 25(1): 18-35. https://doi.org/10.1111/dom.14863
11. Weghuber D, Barrett T, Barrientos-Pérez M, Gies I, Hesse D, Jeppesen OK, et al. Once-weekly semaglutide in adolescents with obesity. N Engl J Med. 2022; 387(24): 2245-2257. https://doi.org/10.1056/NEJMoa2208601
12. Deng Y, Park A, Zhu L, Xie W, Pan CQ. Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review. Ther Adv Chronic Dis. 2022; 13: 20406223221108064. https://doi.org/10.1177/20406223221108064
13. Chaudhry A, Gabriel B, Noor J, Jawad S, Challa SR. Tendency of semaglutide to induce gastroparesis: a case report. Cureus. 2024; 16(1): e52564. https://doi.org/10.7759/cureus.52564
14. Grover M, Farrugia G, Stanghellini V. Gastroparesis: a turning point in understanding and treatment. Gut. 2019; 68(12): 2238-2250. https://doi.org/10.1136/gutjnl-2019-318712
15. Van den Houte K, Scarpellini E, Verbeure W, Mori H, Schol J, Masuy I, et al. The role of gi peptides in functional dyspepsia and gastroparesis: a systematic review. Front Psychiatry. 2020; 11: 172. https://doi.org/10.3389/fpsyt.2020.00172
16. Shaefer CF Jr, Kushner P, Aguilar R. User's guide to mechanism of action and clinical use of GLP-1 receptor agonists. Postgrad Med. 2015; 127(8): 818-26. https://doi.org/10.1080/00325481.2015.1090295
17. O'Neill ES, Wiegmann AL, Parrella N, Pittman T, Hood K, Kurlander D. Injectable weight loss medications in plastic surgery: what we know, perioperative considerations, and recommendations for the future. Plast Reconstr Surg Glob Open. 2024; 12(1): e5516. https://doi.org/10.1097/GOX.0000000000005516
18. Humphrey CD, Lawrence AC. Implications of ozempic and other semaglutide medications for facial plastic surgeons. Facial Plast Surg. 2023; 39(6): 719-721. https://doi.org/10.1055/a-2148-6321
19. Mayerle J, Sendler M, Hegyi E, Beyer G, Lerch MM, Sahin-Tóth M. Genetics, cell biology, and pathophysiology of pancreatitis. Gastroenterology. 2019; 156(7): 1951-1968.e1. https://doi.org/10.1053/j.gastro.2018.11.081
20. Habtezion A. Inflammation in acute and chronic pancreatitis. Curr Opin Gastroenterol. 2015; 31(5): 395-9. https://doi.org/10.1097/MOG.0000000000000195
21. Brady SM, Kane MP, Busch RS. GLP-1 agonist use in a patient with an explainable cause of pancreatitis. AACE Clinical Case Reports. 2016; 2(2): e82-e85. https://doi.org/10.4158/EP15658.CR
22. Zaïmia N, Obeid J, Varrault A, Sabatier J, Broca C, Gilon P, et al. GLP-1 and GIP receptors signal through distinct β-arrestin 2-dependent pathways to regulate pancreatic β cell function. Cell Rep. 2023; 42(11): 113326. https://doi.org/10.1016/j.celrep.2023.113326
23. Chis BA, Fodor D. Acute pancreatitis during GLP-1 receptor agonist treatment. a case report. Clujul Med. 2018; 91(1): 117-119. https://doi.org/10.15386/cjmed-804
24. Knapen LM, de Jong RG, Driessen JH, Keulemans YC, van Erp NP, De Bruin ML, et al. Use of incretin agents and risk of acute and chronic pancreatitis: a population-based cohort study. Diabetes Obes Metab. 2017; 19(3): 401-411. https://doi.org/10.1111/dom.12833
25. Li L, Shen J, Bala MM, Busse JW, Ebrahim S, Vandvik PO, et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BMJ. 2014; 348: g2366. https://doi.org/10.1136/bmj.g2366
26. Aaseth J, Ellefsen S, Alehagen U, Sundfør TM, Alexander J. Diets and drugs for weight loss and health in obesity – an update. Biomed Pharmacother. 2021; 140: 111789. https://doi.org/10.1016/j.biopha.2021.111789
27. Jensen AB, Renström F, Aczél S, Folie P, Biraima-Steinemann M, Beuschlein F, et al. Efficacy of the glucagon-like peptide-1 receptor agonists liraglutide and semaglutide for the treatment of weight regain after bariatric surgery: a retrospective observational study. Obes Surg. 2023; 33(4): 1017-1025. https://doi.org/10.1007/s11695-023-06484-8
28. Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022; 24(8): 1553-1564. https://doi.org/10.1111/dom.14725
29. Klausen MK, Thomsen M, Wortwein G, Fink-Jensen A. The role of glucagon-like peptide 1 (GLP-1) in addictive disorders. Br J Pharmacol. 2022; 179(4): 625-641. https://doi.org/10.1111/bph.15677
30. Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021; 325(14): 1414-1425. https://doi.org/10.1001/jama.2021.3224
31. Patel F, Gan A, Chang K, Vega KJ. Acute pancreatitis in a patient taking semaglutide. Cureus. 2023; 15(8): e43773. https://doi.org/10.7759/cureus.43773
Copyright: © 2024 Pope John Paul II State School of Higher Education in Biała Podlaska. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.